76005-99-7

Usage

Uses

Used in Pharmaceutical Industry:
2-METHOXY-3-AMINO-4-PICOLINE is used as a building block for the synthesis of various pharmaceuticals, including anti-inflammatory and anticancer agents. Its unique structure allows it to be a key component in the development of new drugs with potential therapeutic benefits.
Used in Organic Synthesis:
2-METHOXY-3-AMINO-4-PICOLINE is employed as a versatile intermediate in organic synthesis, enabling the creation of a wide range of chemical compounds for various applications.
Used as a Ligand in Coordination Chemistry:
In coordination chemistry, 2-METHOXY-3-AMINO-4-PICOLINE serves as a ligand, forming complexes with metal ions. This application is crucial for the development of new materials with specific properties and potential uses in various fields.
It is important to handle and store 2-METHOXY-3-AMINO-4-PICOLINE with care due to its potential hazards, ensuring safety and proper usage in the respective industries.

InChI:InChI=1/C7H10N2O/c1-5-3-4-9-7(10-2)6(5)8/h3-4H,8H2,1-2H3

Upstream product

• 160590-36-3 2-methoxy-4-methyl-3-nitropyridine 
• 67-56-1 methanol 
• 133627-45-9 3-Amino-2-chloro-4-methylpyridine 

Downstream Products

• 1417332-43-4 3,6-Dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid (2-methoxy-4-methyl-pyridin-3-yl)-amide 
• 76006-25-2 7-anilino-1H-pyrazolo<3,4-c>pyridine 
• 76006-10-5 7-methoxy-1H-pyrazolo<3,4-c>pyridine 
• 76006-09-2 1H-pyrazolo<3,4-c>pyridin-7(6H)-one 
• 76006-11-6 7-chloro-1H-pyrazolo<3,4-c>pyridine 

Relevant academic research and scientific papers

A pyrazolopyridine compound and method for preparing the same

The invention relates to a pyrazolopyridine compound and a preparation method thereof. The compound is 3-bromo-1H-pyrazolo[3,4-c]pyridine-7(6H)-one, and the preparation method comprises the following steps: (1) by taking the compound 1 2-chloro-3-amino-4methylpyridine as a starting raw material, etherifying 2-chloro-3-amino-4methylpyridine through sodium methoxide under the catalysis of copper iodide; (2) closing pyrazole ring through isoamyl nitrite; (3) feeding pyrazol-3 through NBS (N-Bromosuccinimide); (4) removing methoxyl to obtain phenyl (mixture difficult to separate) through pyridine hydrochloride; (5) performing acetyl protection to the obtained mixture so as to separate and purify; and (6) deacetylating through using potassium carbonate as a base to obtain a final product; and according to the preparation method, the mixture difficult to purify in the reaction process is conveniently separated and purified by adopting a method of performing protection and then removing protection, and the purification difficulty caused by instability of an intermediate product can be solved.

A pyrazole compound pyridine and its preparation method

The invention relates to a pyrazolo pyridine compound and a preparation method thereof. The pyrazolo pyridine compound is 3-bromine-7-hydroxy-pyrazolo pyridine. The preparation method comprises the following steps: (1) carrying out substitution reaction on 12-chlorine-4-methyl-3-aminopyridine as an initial raw material to form a compound 2; (2) carrying out ring closure on the compound 2 to form a compound 3, namely pyrazolo pyridine; (3) bromizing the compound 3 by adopting N-bromosuccinimide to obtain a compound 4; (4) forming the methoxyl of the compound 4 into a phenolic hydroxyl group by utilizing hydrochloric pyridine to obtain a compound 5a; (5) carrying out acetyl protection on the compound 5a to obtain a compound 6a; and (6) eliminating the acetyl protection on the compound 6 to obtain a final product, namely a compound 7. The obtained final product has a wide application prospect on the aspects of preventing and curing cancer.

NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR

The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine alpha7 receptor.

PYRAZOLOPYRIDINES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM

The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said com- pounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor.

Synthesis and antiviral activity evaluation of some novel acyclic C-nucleosides

The preparation of novel 5-amino or 7-hydroxy substituted pyrazolo[4,3-b]pyridine and pyrazolo[3,4-c]pyridine acyclic C-nucleosides is described. Their synthesis was carried out by condensation of suitably substituted lithiated picolines with 2-benzyloxyethoxymethylchloride followed by pyrazole ring annulation. The compounds were evaluated for their antiviral activity against a wide panel of viruses, but were found inactive at subtoxic concentrations.

Method for preparing alkyl-5,11-dihydro-6h-dipyrido[3,2-B:2',3'-E] [1,4] diazepin-6-ones

A method for preparing certain 4-alkyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-ones, which employs the following reaction scheme: STR1

Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)

Compounds of the formula STR1 wherein R21 and R22 are as defined in the specification which are intermediates useful in the preparation of compounds of the formula STR2 and the pharmaceutically acceptable salts thereof, wherein Q and R1 are as defined in the specification. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.

New N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase

Compounds of the formula the pharmaceutically acceptable salts thereof, wherein Q and R1 are as defined below, and novel carboxylic acid and acid halide intermediates used in the synthesis of such compounds. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.